State of New Jersey Common Pension Fund D grew its stake in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 75.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 210,000 shares of the biotechnology company’s stock after acquiring an additional 90,000 shares during the period. State of New Jersey Common Pension Fund D owned 0.32% of Sarepta Therapeutics worth $33,917,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Waddell & Reed Financial Inc. bought a new position in Sarepta Therapeutics during the second quarter worth about $103,682,000. Millennium Management LLC grew its holdings in Sarepta Therapeutics by 242.2% during the second quarter. Millennium Management LLC now owns 858,407 shares of the biotechnology company’s stock worth $113,464,000 after purchasing an additional 607,588 shares during the period. Boxer Capital LLC bought a new position in Sarepta Therapeutics during the second quarter worth about $49,568,000. Macquarie Group Ltd. grew its holdings in Sarepta Therapeutics by 444.0% during the second quarter. Macquarie Group Ltd. now owns 383,093 shares of the biotechnology company’s stock worth $50,637,000 after purchasing an additional 312,670 shares during the period. Finally, RTW Investments LP grew its holdings in Sarepta Therapeutics by 42.2% during the second quarter. RTW Investments LP now owns 978,551 shares of the biotechnology company’s stock worth $129,345,000 after purchasing an additional 290,280 shares during the period. Institutional investors own 89.99% of the company’s stock.

Shares of SRPT stock opened at $141.99 on Thursday. The company has a debt-to-equity ratio of 0.62, a current ratio of 10.88 and a quick ratio of 9.89. The company has a market cap of $10.73 billion, a price-to-earnings ratio of -86.58 and a beta of 1.15. Sarepta Therapeutics Inc has a 12-month low of $46.07 and a 12-month high of $176.50.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.99). The company had revenue of $73.53 million for the quarter, compared to analyst estimates of $71.53 million. Sarepta Therapeutics had a negative return on equity of 19.34% and a negative net margin of 89.64%. The company’s revenue was up 110.0% on a year-over-year basis. During the same quarter last year, the business earned ($0.48) earnings per share. On average, sell-side analysts anticipate that Sarepta Therapeutics Inc will post -3.67 EPS for the current fiscal year.

A number of equities analysts recently commented on SRPT shares. Piper Jaffray Companies reiterated an “overweight” rating and set a $168.00 price target on shares of Sarepta Therapeutics in a report on Wednesday, June 20th. Barclays reiterated an “overweight” rating and set a $180.00 price target on shares of Sarepta Therapeutics in a report on Wednesday, June 20th. Leerink Swann reiterated an “outperform” rating on shares of Sarepta Therapeutics in a report on Wednesday, June 20th. Cowen reiterated an “outperform” rating and set a $178.00 price target on shares of Sarepta Therapeutics in a report on Wednesday, June 20th. Finally, Morgan Stanley lifted their price target on Sarepta Therapeutics from $91.00 to $163.00 and gave the stock an “equal weight” rating in a report on Wednesday, June 20th. Two research analysts have rated the stock with a hold rating, twenty-five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Sarepta Therapeutics has an average rating of “Buy” and an average price target of $169.28.

In related news, CEO Douglas S. Ingram acquired 16,000 shares of the business’s stock in a transaction on Wednesday, August 15th. The stock was purchased at an average cost of $125.26 per share, for a total transaction of $2,004,160.00. Following the completion of the transaction, the chief executive officer now directly owns 399,250 shares of the company’s stock, valued at approximately $50,010,055. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 7.90% of the company’s stock.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

Read More: NASDAQ Stock Market Explained

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.